statnews.com·Feb 17, 2026
Ocular Therapeutix's experimental eye drug, Axpaxli, outperformed a low dose of Regeneron's Eylea in a late-stage trial for wet age-related macular degeneration, maintaining vision with fewer injections, but its commercial potential remains uncertain due to narrower-than-expected efficacy differences.
Ocular Therapeutix's Axpaxli has demonstrated superiority over a low dose of Regeneron’s Eylea in maintaining vision for wet age-related macular degeneration in a late-stage trial. This result positions Axpaxli for potential FDA approval, offering an investment opportunity in a competitive market, though its commercial success will depend on its perceived advantage over existing treatments.